Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wake Forest University Health Sciences
With
National Cancer Institute (NCI)
OBJECTIVES:
I. The objective of this study is to describe outcomes associated with prolonged infusion (3 hours) compared to standard infusion (30 minutes) cefepime (cefepime hydrochloride) among patients being treated empirically for febrile neutropenia.
OUTLINE: Patients are randomized 1 of 2 treatment arms.
All patients receive cefepime hydrochloride intravenously (IV) over 30 minutes as their first dose.
ARM I: Patients receive cefepime hydrochloride intravenously (IV) over 30 minutes.
ARM II: Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Absolute neutrophil count \< 500 cells/mm\^3 or \< 1000 cells/mm\^3 with a predicted decrease to \< 500 cells/mm\^3
Temperature \> 38.0 degrees Celsius
Received chemotherapy or stem-cell transplant as treatment for malignancy or myelodysplastic syndrome (MDS)
Cefepime prescribed at a dose of 2 grams IV every 8 hours
